ISTA Pharmaceuticals Reports Third Quarter 2009 Financi...(facilities products and/or business; unc...)

Date:11/3/2009

facilities, products and/or business; uncertainties and risks related to the scope, validity, and enforceability of patents related to ISTA's products and technologies and the impact of patents and other intellectual property rights held by third parties; and such other risks and uncertainties as detailed from time to time in ISTA's public filings with the U.S. Securities and Exchange Commission, including but not limited to ISTA's Annual Report on Form 10-K for the year ended December 31, 2008 and ISTA's Quarterly Reports on Form 10-Q for the quarters ended March 31, 2009, and June 30, 2009.

                             ISTA Pharmaceuticals, Inc.
                     Consolidated Statements of Operations
                      (in thousands, except per share data)
                                   (unaudited)

                                     Three Months Ended   Nine Months Ended
                                        September 30,       September 30,
                                       2009      2008      2009      2008
                                               Adjusted           Adjusted
    Revenue:
      Product sales, net             $29,080   $21,604   $73,309   $54,749
      License revenue                  2,917        69     3,055       208
                                     -------   -------   -------   -------
    Total revenue                     31,997    21,673    76,364    54,957
    Cost of products sold              7,304     5,806    18,647    14,761
                                     -------   -------   -------   -------
    Gross profit margin               24,693    15,867    57,717    40,196
    Costs and expenses:
      Research and development         6,257     7,766    19,643    25,053
      Selling, general, and
       administrative                 13,187    13,198    38,874    40,150
                                     -------   -------   -------   -------
    Total costs and expenses          19,444    20,96
'/>"/>
SOURCE  ISTA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 
Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs